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Introduction
Most anti-inflammatory drugs have been associated with
gastrointestinal side effects. Gastrointestinal mucosa
damage can range from endoscopic lesions with no clinical
manifestations to serious upper gastrointestinal complica-
tions (UGIC) that, in some instances, may be fatal. Because
of their relatively low incidence, severe gastrointestinal
events can only be effectively evaluated in large, post-
marketing, observational studies. This document presents
epidemiological evidence of the magnitude of the risk of
upper gastrointestinal tract bleeding or perforation among
users of anti-inflammatory drugs: oral steroids, aspirin,
nonaspirin nonsteroidal anti-inflammatory drugs
(NA-NSAIDs), and acetaminophen (paracetamol in Europe).
Two methods will be used to examine the interaction
resulting from multiple use of anti-inflammatory drugs on
the risk of UGIC: firstly, we shall review epidemiological
findings published by other authors [1–10]; and, secondly,
we shall summarize results published by our group
[11–13]. These cited papers provide a more detailed
description of the methodology.
Our data was based on a nested case–control study
carried out in the UK General Practice Research Data-
base (GPRD) for the period 1993–1998. The study popu-
lation consisted of 958,397 persons aged 40–79 years
who had been enrolled for at least 2 years, and who were
free of cancer, esophageal varices, Mallory–Weiss
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disease, liver disease, coagulopathies and alcohol-related
disorders at the start date. All members of the source pop-
ulation were followed-up until they met a case definition
criterion or an exclusion criterion, or until they died. We
identified patients with codes for UGIC and manually
reviewed the demographic data and clinical information in
the computerized patient profiles. We excluded subjects
with any of the risk factors already mentioned in the
2 months after the date of case detection, and excluded
subjects in whom the sources of the bleeding and perfora-
tion were the esophagus or lower gastrointestinal tract. A
patient was considered to have UGIC when no exclusion
criterion was found, the subject had not been hospitalized
in the previous month, and the specific site of the bleeding
and perforation was located in the stomach or duodenum.
Control subjects were frequency matched by age and
gender, with the same exclusion criteria for patients also
being applied to the control subjects. The analysis
included 2105 patients and 11,500 control subjects. We
used unconditional logistic regression to compute esti-
mates of relative risk (RR) and 95% confidence intervals
(CI) of UGIC associated with current use of steroids,
aspirin, NA-NSAIDs, and acetaminophen. All estimates of
RR were adjusted for age, sex, calendar year, smoking,
antecedents of upper gastrointestinal disorders, and con-
comitant medications (including anticoagulants, misopros-
tol, H2-receptor antagonists, omeprazole and nitrates).
Steroids
The literature on the gastrointestinal safety of oral
steroids is controversial. Results from early clinical trials
were interpreted both as a dose-dependent increased
risk of peptic ulcers in the groups treated with steroids
[14], and as no difference between the steroid and
placebo groups [15]. Results from epidemiological
studies have been heterogeneous and were often based
on small numbers (pooled RR estimate, 1.9; 95% CI,
1.5–2.4) [1–6].
Two percent of controls in the GPRD had used oral
steroids in the past month. Prednisolone accounted for
more than 85% of systemic steroid use. The risk of
UGIC was 1.8 (95% CI, 1.3–2.4) times higher for users
of steroids than for non-users. The risk tended to be
greater for steroid doses equivalent to or above 30mg
prednisone than for lower doses, although this dose
response was not statistically significant (Table 1)
[11,12].
Aspirin
Epidemiological studies have reported risks of UGIC
from one to 10 times higher among aspirin users, with an
estimated pooled relative risk between 2 and 3 [16–18].
The risk associated with aspirin was dose dependent but
was still present at low daily doses (300mg) [7–10] or
even at very low daily doses (75mg) [9,10].
Seven percent of controls in our population had used
aspirin in the past month. The adjusted RR of UGIC for
low dose aspirin users was 2.0 (95% CI, 1.6–2.6), as
compared with non-users. No clear dose effect was
found within the range of 75–300mg (Table 1) [13].
Nonaspirin NSAIDs
Intake of NA-NSAIDs as a group has been consistently
associated with a four- to fivefold increase in UGIC
[16–19]. The risk is clearly dose dependent. The esti-
Table 1
Relative risk (RR) and 95% confidence interval (CI) of upper
gastrointestinal complications associated with use of steroids,
aspirin, nonaspirin nonsteroidal anti-inflammatory drugs (NA-
NSAIDs), and acetaminophen
Cases Controls
(n=2105) (n=11,500) RR* 95% CI
Steroids†
Non-use 1724 9824 Reference
Current 90 196 1.8 1.3–2.4
Low–medium dose† 75 174 1.5 1.1–2.1
High dose 9 13 2.9 1.2–7.3
Aspirin
Non-use 1696 10,157 Reference
Current 287 837 2.1 1.8–2.5
75mg 140 420 2.0 1.6–2.6
150mg 90 248 2.2 1.7–2.9
³300mg‡ 57 169 2.2 1.6–3.1
NA-NSAIDs
Non-use 1468 9746 Reference
Current 438 758 4.1 3.6–4.8
Low–medium dose§ 92 290 2.4 1.9–3.2
High dose§ 311 449 4.7 3.9–5.6
Acetaminophen
Non-use 1494 9532 Reference
Current 376 1069 1.3 1.1–1.5
<2g 201 852 0.9 0.8–1.1
2g 84 127 1.9 1.4–2.6
³2g 91 90 3.7 2.6–5.1
Data are for United Kingdom General Practice Research Database,
1993–1998. *Adjusted for age, sex, calendar year, ulcer history,
smoking, and concomitant medication. These analyses include only
current users versus non-users (no use in the past 180 days); data on
recent past (between 30 and 180 days) users are not presented.
†There were 15 subjects with missing values for oral steroid dose. The
cut-off point was 30mg prednisolone or equivalent. ‡There were only
eight cases and nine controls who were taking doses greater than
300mg. §These analyses include only users of a single NA-NSAID.Arthritis Research    Vol 3 No 2 García Rodríguez and Hernández-Díaz
mated pooled RRs in a recent meta-analysis were 3.0
(95% CI, 2.6–3.4) for low doses, 4.1 (95% CI, 3.6–4.5)
for medium doses, and 6.9 (95% CI, 5.8–8.1) for high
doses [19].
Seven percent of controls in our population had used
NA-NSAIDs in the past week. We found a RR of 4.1 (95%
CI, 3.6–4.8) for NA-NSAIDs studied as a therapeutic
class. Users of low/medium daily doses had a RR of 2.4,
whereas users of high daily doses had a fivefold increase
in risk (Table 1) [11].
Acetaminophen
Epidemiological data on the association between aceta-
minophen use and UGIC are limited and inconsistent
(pooled RR, 1.4; 95% CI, 1.0–2.0) [2,8,20–22]. However,
two studies evaluated the effect of dose, and both
reported an increased risk of UGIC associated with use of
acetaminophen at high doses (ie anti-inflammatory doses)
[8,23].
Nine percent of controls in the GPRD had used aceta-
minophen in the past month. Overall, use of aceta-
minophen was associated with a negligible elevated risk of
UGIC (RR, 1.3; 95% CI, 1.1–1.5). We found an increased
risk of UGIC among current users of acetaminophen at
doses greater than 2g (RR, 3.7; 95% CI, 2.6–5.1),
whereas doses below 2g did not carry an increased risk
(Table 1).
Concomitant medication
The use of oral steroids has been found to reinforce the
risk of UGIC associated with NA-NSAIDs [16,24]. The
risk was shown to be more than 12 times higher for con-
comitant users of both steroids and NA-NSAIDs, com-
pared with non-users of either drug [1,5]. Users of
multiple NA-NSAIDs simultaneously had about 10 times
increased risk of developing UGIC, compared with non-
users [5,6,11]. The risk associated with simultaneous
use of aspirin and NA-NSAIDs, in contrast, was only
slightly higher than the sum of their individual risks [7].
Concomitant use of aspirin together with NA-NSAIDs at
high dose, however, increased substantially the risk of
UGIC [9].
The RR values in our population, compared with those of
non-users of any anti-inflammatory drug, were 8.5 (95%
CI, 3.9–18.9) for current users of steroids and
NA-NSAIDs, 3.1 (95% CI, 1.2–8.1) for users of steroids
and aspirin, and 4.8 (95% CI, 1.1–20.9) for users of
steroids and high doses of acetaminophen (³2g) (the
latter two estimates are based on a small number of
exposed patients). The corresponding RR value for
current users of aspirin and NA-NSAIDs was 8.2 (95%
CI, 5.3–12.8), and that for current users of aspirin and
high doses of acetaminophen was 3.3 (95% CI,
1.7–6.5). We found a substantial interaction between
NA-NSAIDs and high dose acetaminophen; compared
with non-users of either drugs, the RR for concurrent
users of NA-NSAIDs and acetaminophen (³2g) was
16.6 (95% CI, 11.0–24.9). Concomitant users of three
or four anti-inflammatory drugs (excluding low dose
acetaminophen) presented a relative risk of 18.0 (95%
CI, 9.0–36.1) compared with persons not exposed to
any of the anti-inflammatory drugs (Table 2).
Conclusion
In summary, use of oral steroids, aspirin and acetaminophen
at doses ³2g are each associated with around twofold
Table 2
Relative risk (RR) and 95% confidence interval (CI) of upper
gastrointestinal complications associated with combined use
of anti-inflammatory drugs
Anti-inflammatory
drugs Cases (n) Controls (n) RR* 95% CI
None† 852 6768 Reference
Steroids alone 41 132 2.1 1.4–3.0
Aspirin alone 177 609 2.4 1.9–2.9
NA-NSAIDs alone 193 489 3.6 2.9–4.3
Acetaminophen (<2g) 96 565 1.1 0.9–1.4
Acetaminophen (³2g) 52 124 2.4 1.7–3.5
Steroids and aspirin 6 17 3.1 1.2–8.1
Steroids and NA-NSAIDs14 13 8.5 3.9–18.9
Steroids and 5 31 1.1 0.4–2.9
acetaminophen (<2g)
Steroids and 4 5 4.8 1.1–20.9
acetaminophen (³2g)
Aspirin and NA-NSAIDs 40 50 8.2 5.3–12.8
Aspirin and 16 94 1.3 0.7–2.3
acetaminophen (<2g)
Aspirin and 14 32 3.3 1.7–6.5
acetaminophen (³2g)
NA-NSAIDs and 61 134 4.1 3.0–5.7
acetaminophen (<2g)
NA-NSAIDs and 80 41 16.6 11.0–24.9
acetaminophen (³2g)
Three or four 27 13 18.0 9.0–36.1
anti-inflammatory drugs‡
Data are for United Kingdom General Practice Research Database,
1993–1998. NA-NSAIDs, Nonaspirin nonsteroidal anti-inflammatory
drugs. *Adjusted for age, sex, calendar year, ulcer history, smoking,
and concomitant medications. These analyses include only current
users versus non-users (no use in the past 180 days); data on recent
past (between 30 and 180 days) users are not presented. †Patients
exposed to no drug (steroids, aspirin, NA-NSAIDs, and
acetaminophen). Categories are mutually exclusive. ‡Acetaminophen at
doses <2g not included in this category.Available online http://arthritis-research.com/content/3/2/098
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increased risk of upper gastrointestinal complications;
NA-NSAIDs are associated with a close to fourfold
increased risk. Dose is an important predictor of the risk of
UGIC for all anti-inflammatory drugs. For instance, we
found that acetaminophen was associated with an
increased risk only when taken at daily doses ³2g. The
use of NA-NSAIDs concomitantly with oral steroids,
aspirin, or high doses of acetaminophen increases the risk
of UGIC greater than eightfold.
The incidence of hospitalization for complicated peptic
ulcer disease among non-users of anti-inflammatory drugs
is approximately one case per 1000 persons per year in
the general population [5,25,26]. The number of UGIC
events per 1000 persons per year, based on epidemiolog-
ical studies, would be two events among steroid users,
two events among aspirin users, and between four and
five events among NA-NSAID users. The incidence would
be higher for users of high doses of any anti-inflammatory
drugs and for patients taking more than one anti-inflamma-
tory drug simultaneously. For example, the incidence
would be around eight cases per 1000 users of steroids
and NA-NSAIDs or per 1000 users of aspirin and
NA-NSAIDs concomitantly per year. The absolute risk in
the small subgroup of patients that take concomitantly
three or four different anti-inflammatory drugs would
augment close to 20 per 1000 users (2% per year).
In conclusion, whenever possible, any anti-inflammatory
drug should be given in monotherapy and at the lowest
effective dose in order to reduce the risk of UGIC.
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